Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 238
Gene Symbol: ALK
ALK
0.050 Biomarker disease BEFREE Presence of anaplastic lymphoma kinase (ALK) rearrangement is an indication for crizotinib in the treatment of patients with advanced or metastatic lung adenocarcinoma. 28118634 2017
Entrez Id: 238
Gene Symbol: ALK
ALK
0.050 Biomarker disease BEFREE Effectiveness of crizotinib in a patient with ALK IHC-positive/FISH-negative metastatic lung adenocarcinoma. 27393517 2016
Entrez Id: 238
Gene Symbol: ALK
ALK
0.050 GeneticVariation disease BEFREE In the current study, the authors evaluated their experience with the identification of epidermal growth factor receptor (EGFR), Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation, and anaplastic lymphoma kinase (ALK) gene rearrangement using cytological specimens of primary and metastatic lung adenocarcinoma. 23495083 2013
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.040 Biomarker disease BEFREE Here, we sought to characterize tumor proteome and phosphoproteome changes by longitudinal, prospective collection of tumor tissue from an exceptional responder lung adenocarcinoma patient who survived with metastatic lung adenocarcinoma for over seven years while undergoing HER2-directed therapy in combination with chemotherapy. 30617155 2019
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.040 GeneticVariation disease BEFREE Here we report the outcomes of nine patients with metastatic lung adenocarcinoma with ERBB2 mutations being treated with ERBB2-targeted therapies. 28167203 2017
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.040 Biomarker disease BEFREE EGFR, KRAS, BRAF and HER2 testing in metastatic lung adenocarcinoma: Value of testing on samples with poor specimen adequacy and analysis of discrepancies. 29175303 2017
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.040 GeneticVariation disease BEFREE Successful treatment of a patient with Li-Fraumeni syndrome and metastatic lung adenocarcinoma harboring synchronous EGFR L858R and ERBB2 extracellular domain S310F mutations with the pan-HER inhibitor afatinib. 24835218 2014
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.030 GeneticVariation disease BEFREE The third patient, a 62-year-old female with metastatic lung adenocarcinoma, had allelic p.P278S (GOF) and p.R283L (non-GOF) variants at frequencies of 61% but with null staining for p53. 29666004 2018
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.030 GeneticVariation disease BEFREE Genetic examination revealed mutations in EGFR and p53 that were of the same type as the lung tumor, leading to the final diagnosis of the femoral mass as a sarcomatous transformation of metastatic lung adenocarcinoma. 26045851 2015
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.030 AlteredExpression disease BEFREE Fibulin-2 was abundant in the extracellular matrix of human lung adenocarcinomas and was highly expressed in tumor cell lines derived from mice that develop metastatic lung adenocarcinoma from co-expression of mutant K-ras and p53. 23785517 2013
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.030 GeneticVariation disease BEFREE Comparison of EGFR and KRAS mutations in primary and unpaired metastatic lung adenocarcinoma with potential chemotherapy effect. 23337026 2013
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.030 GeneticVariation disease BEFREE In the current study, the authors evaluated their experience with the identification of epidermal growth factor receptor (EGFR), Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation, and anaplastic lymphoma kinase (ALK) gene rearrangement using cytological specimens of primary and metastatic lung adenocarcinoma. 23495083 2013
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.030 GeneticVariation disease BEFREE In this study, we have investigated EGFR and KRAS mutations in metastatic lung adenocarcinoma. 21497370 2011
Entrez Id: 5979
Gene Symbol: RET
RET
0.020 GeneticVariation disease BEFREE Resistance to vandetanib, a type I RET kinase inhibitor, developed in a patient with metastatic lung adenocarcinoma harboring a CCDC6-RET fusion that initially exhibited a response to treatment. 29434222 2018
Entrez Id: 8030
Gene Symbol: CCDC6
CCDC6
0.020 GeneticVariation disease BEFREE Resistance to vandetanib, a type I RET kinase inhibitor, developed in a patient with metastatic lung adenocarcinoma harboring a CCDC6-RET fusion that initially exhibited a response to treatment. 29434222 2018
Entrez Id: 673
Gene Symbol: BRAF
BRAF
0.020 GeneticVariation disease BEFREE In this report, we describe the case of a 71-year-old man who developed classic GA lesions while being treated with vemurafenib monotherapy for nonmelanoma cancer, specifically metastatic lung adenocarcinoma positive for BRAF V600 mutation.<p><em>J Drugs Dermatol.2017;16(10):1050-1052.</em></p>. 29036262 2017
Entrez Id: 8030
Gene Symbol: CCDC6
CCDC6
0.020 Biomarker disease BEFREE Multiplex reverse transcription-polymerase chain reaction (RT-PCR) was used to detect KIF5B-RET and CCDC6-RET fusions from specimens of malignant pleural effusion (MPE) in patients with metastatic lung adenocarcinoma. 25773866 2015
Entrez Id: 5979
Gene Symbol: RET
RET
0.020 Biomarker disease BEFREE Multiplex reverse transcription-polymerase chain reaction (RT-PCR) was used to detect KIF5B-RET and CCDC6-RET fusions from specimens of malignant pleural effusion (MPE) in patients with metastatic lung adenocarcinoma. 25773866 2015
Entrez Id: 673
Gene Symbol: BRAF
BRAF
0.020 GeneticVariation disease BEFREE Here, we report the case of a patient with metastatic lung adenocarcinoma with BRAF G469L mutation refractory to vemurafenib. 24035431 2013
Entrez Id: 6098
Gene Symbol: ROS1
ROS1
0.010 Biomarker disease BEFREE We evaluated the diagnostic accuracy and interpathologist agreement of two anti-ROS1 IHC clones, SP384 (Ventana, Tucson, Arizona) and D4D6 (Cell Signaling, Danvers, Massachusetts), in a training cohort of 51 positive ROS1 FISH LUAD cases, and then in a large validation cohort of 714 consecutive cases of LUAD from six routine molecular pathology platforms. 30999109 2019
Entrez Id: 29126
Gene Symbol: CD274
CD274
0.010 GeneticVariation disease BEFREE We report a patient with brain metastatic lung adenocarcinoma in whom fatal myocarditis developed after sequential use of PD-1 and PD-L1 inhibitors. 31022941 2019
Entrez Id: 94025
Gene Symbol: MUC16
MUC16
0.010 Biomarker disease BEFREE To examine the serum levels of carcinoembryonic antigen (CEA), cytokeratin-19 fragments (CYFRA21-1), neuron-specific enolase (NSE), carbohydrate antigen (CA) 19-9, CA125, tissue polypeptide antigen (TPA), tissue polypeptide specific antigen (TPS), and lactate dehydrogenase (LDH) to predict de novo metastatic lung adenocarcinoma. 31356196 2019
Entrez Id: 3880
Gene Symbol: KRT19
KRT19
0.010 Biomarker disease BEFREE To examine the serum levels of carcinoembryonic antigen (CEA), cytokeratin-19 fragments (CYFRA21-1), neuron-specific enolase (NSE), carbohydrate antigen (CA) 19-9, CA125, tissue polypeptide antigen (TPA), tissue polypeptide specific antigen (TPS), and lactate dehydrogenase (LDH) to predict de novo metastatic lung adenocarcinoma. 31356196 2019
Entrez Id: 1048
Gene Symbol: CEACAM5
CEACAM5
0.010 AlteredExpression disease BEFREE To examine the serum levels of carcinoembryonic antigen (CEA), cytokeratin-19 fragments (CYFRA21-1), neuron-specific enolase (NSE), carbohydrate antigen (CA) 19-9, CA125, tissue polypeptide antigen (TPA), tissue polypeptide specific antigen (TPS), and lactate dehydrogenase (LDH) to predict de novo metastatic lung adenocarcinoma. 31356196 2019
Entrez Id: 2150
Gene Symbol: F2RL1
F2RL1
0.010 Biomarker disease BEFREE Our finding also suggests that PAR2 might serve as a therapeutic target for metastatic lung adenocarcinoma and a potential biomarker for predicting the prognosis of lung adenocarcinoma. 30321617 2019